Bessemer Group Inc. raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 128.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,468,137 shares of the company's stock after acquiring an additional 1,387,722 shares during the quarter. Bessemer Group Inc. owned approximately 0.10% of Merck & Co., Inc. worth $358,647,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently modified their holdings of MRK. Bullseye Investment Management LLC purchased a new stake in Merck & Co., Inc. in the 2nd quarter worth approximately $27,000. Curry Webb Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at $29,000. Horizons Wealth Management purchased a new stake in Merck & Co., Inc. in the 3rd quarter worth $30,000. Graney & King LLC increased its stake in Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company's stock worth $32,000 after buying an additional 200 shares in the last quarter. Finally, Montgomery Financial Services LLC bought a new stake in Merck & Co., Inc. during the second quarter valued at about $41,000. Institutional investors own 76.07% of the company's stock.
Key Stories Impacting Merck & Co., Inc.
Here are a few of the latest stories about MRK:
- Positive Sentiment: The EMA’s CHMP recommended expanding ENFLONSIA’s use to help prevent severe RSV lower respiratory tract disease in vulnerable children up to 24 months old, including through their second RSV season. The broader eligible population could support the medicine’s commercial opportunity in Europe. Merck ENFLONSIA CHMP recommendation
- Positive Sentiment: The CHMP also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cell carcinoma after anti-PD-1/PD-L1 treatment. This would extend WELIREG into another treatment setting and expand Merck’s oncology portfolio in Europe. Merck WELIREG CHMP recommendation
- Neutral Sentiment: Both decisions are CHMP recommendations; European Commission approval is still needed. Any financial contribution will also depend on launch timing, uptake and competition.
Merck & Co., Inc. Trading Down 0.0%
Shares of MRK opened at $147.74 on Monday. The company's fifty day moving average is $146.16 and its 200 day moving average is $128.61. Merck & Co., Inc. has a fifty-two week low of $91.49 and a fifty-two week high of $156.92. The stock has a market capitalization of $364.21 billion, a PE ratio of 152.31, a P/E/G ratio of 6.77 and a beta of 0.13. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The company had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the prior year, the firm earned $2.58 earnings per share. Merck & Co., Inc.'s revenue was up 4.7% on a year-over-year basis. Sell-side analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts have recently commented on the company. Royal Bank Of Canada lowered their price objective on Merck & Co., Inc. from $145.00 to $140.00 and set a "sector perform" rating on the stock in a research report on Friday, October 30th. Cantor Fitzgerald upped their price objective on Merck & Co., Inc. from $145.00 to $155.00 and gave the stock a "neutral" rating in a research note on Monday, November 2nd. Daiwa Securities Group upgraded Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 target price for the company in a research report on Wednesday, August 12th. JPMorgan Chase & Co. lifted their target price on Merck & Co., Inc. from $165.00 to $175.00 and gave the company an "overweight" rating in a research note on Friday, October 30th. Finally, Jefferies Financial Group lifted their target price on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $155.74.
View Our Latest Analysis on Merck & Co., Inc.
Merck & Co., Inc. Profile
(
Free Report)
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.